JESTI BREAUX: Open Payments
NPI 1710692181 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$821 in 40 payments from 11 companies in 2025. Trend: 2023 $928 · 2024 $515 · 2025 $821
Food & beverage: $821
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 11 | $246 |
| Mayne Pharma Commercial LLC | 7 | $175 |
| Exeltis, USA Inc. | 9 | $148 |
| Sumitomo Pharma America, Inc. | 5 | $103 |
| SHIELD THERAPEUTICS INC | 2 | $34 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| PFIZER INC. | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $18 |
| Organon LLC | 1 | $17 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
Products named: Veozah, SLYND, ANNOVERA, MYFEMBREE, ACCRUFER, Exparel, ABRYSVO, ZURZUVAE.
Industry payments across LA — which companies pay providers there.
